Search

Your search keyword '"Andreeff, Michael"' showing total 15 results
Start Over Author "Andreeff, Michael" Journal blood advances
15 results on '"Andreeff, Michael"'

1. Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML

Author

Issa, Ghayas C., Bidikian, Aram, Venugopal, Sangeetha, Konopleva, Marina, DiNardo, Courtney D., Kadia, Tapan M., Borthakur, Gautam, Jabbour, Elias, Pemmaraju, Naveen, Yilmaz, Musa, Short, Nicholas J., Maiti, Abhishek, Sasaki, Koji, Masarova, Lucia, Pierce, Sherry, Takahashi, Koichi, Tang, Guilin, Loghavi, Sanam, Patel, Keyur, Andreeff, Michael, Bhalla, Kapil, Garcia-Manero, Guillermo, Ravandi, Farhad, Kantarjian, Hagop, and Daver, Naval

Published
2023
Full Text
View/download PDF

2. Undetectable Measurable Residual Disease is Associated with Improved Outcomes in AML Irrespective of Treatment Intensity

Author

Bazinet, Alexandre, Kadia, Tapan, Short, Nicholas J., Borthakur, Gautam, Wang, Sa A., Wang, Wei, Loghavi, Sanam, Jorgensen, Jeffrey, Patel, Keyur, DiNardo, Courtney, Daver, Naval, Alvarado, Yesid, Haddad, Fadi G., Pierce, Sherry, Gonzalez, Graciela Nogueras, Maiti, Abhishek, Sasaki, Koji, Yilmaz, Musa, Thompson, Philip, Wierda, William, Garcia-Manero, Guillermo, Andreeff, Michael, Jabbour, Elias, Konopleva, Marina, Huang, Xuelin, Kantarjian, Hagop, and Ravandi, Farhad

Published
2023
Full Text
View/download PDF

4. Exogenous mitochondrial transfer and endogenous mitochondrial fission facilitate AML resistance to OxPhos inhibition

Author

Saito, Kaori, Zhang, Qi, Yang, Haeun, Yamatani, Kotoko, Ai, Tomohiko, Ruvolo, Vivian, Baran, Natalia, Cai, Tianyu, Ma, Helen, Jacamo, Rodrigo, Kuruvilla, Vinitha, Imoto, Junichi, Kinjo, Sonoko, Ikeo, Kazuho, Moriya, Kaori, Suzuki, Koya, Miida, Takashi, Kim, Yong-Mi, Vellano, Christopher P., Andreeff, Michael, Marszalek, Joseph R., Tabe, Yoko, and Konopleva, Marina

Published
2021
Full Text
View/download PDF

5. Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia

Author

Maiti, Abhishek, DiNardo, Courtney D., Wang, Sa A., Jorgensen, Jeffrey, Kadia, Tapan M., Daver, Naval G., Short, Nicholas J., Yilmaz, Musa, Pemmaraju, Naveen, Borthakur, Gautam, Bose, Prithviraj, Issa, Ghayas C., Ferrajoli, Alessandra, Jabbour, Elias J., Jain, Nitin, Garcia-Manero, Guillermo, Ohanian, Maro, Takahashi, Koichi, Montalban-Bravo, Guillermo, Masarova, Lucia, Burger, Jan A., Thompson, Philip A., Verstovsek, Srdan, Sasaki, Koji, Andreeff, Michael, Rausch, Caitlin R., Montalbano, Kathryn S., Pierce, Sherry, Qiao, Wei, Ning, Jing, Kantarjian, Hagop M., Konopleva, Marina Y., and Ravandi, Farhad

Published
2021
Full Text
View/download PDF

6. Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia

Author

Short, Nicholas J., Montalban-Bravo, Guillermo, Hwang, Hyunsoo, Ning, Jing, Franquiz, Miguel J., Kanagal-Shamanna, Rashmi, Patel, Keyur P., DiNardo, Courtney D., Ravandi, Farhad, Garcia-Manero, Guillermo, Takahashi, Koichi, Konopleva, Marina, Daver, Naval, Issa, Ghayas C., Andreeff, Michael, Kantarjian, Hagop, and Kadia, Tapan M.

Published
2020
Full Text
View/download PDF

8. Cigarette smoke exposure accelerates AML progression in FLT3-ITD models

Author

Figueroa, Mary, primary, Ma, Huaxian, additional, Alfayez, Mansour, additional, Morales-Mantilla, Daniel Enrique, additional, Wang, Fei, additional, Lu, Yue, additional, Estecio, Marcos, additional, King, Katherine Y, additional, Kleinerman, Eugenie S., additional, Moghaddam, Seyed Javad, additional, Daver, Naval G., additional, Andreeff, Michael, additional, Konopleva, Marina Y., additional, DiNardo, Courtney D, additional, and Chandra, Joya, additional

Published
2023
Full Text
View/download PDF

9. Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML

Author

Issa, Ghayas C., primary, Bidikian, Aram, additional, Venugopal, Sangeetha, additional, Konopleva, Marina Y., additional, DiNardo, Courtney D., additional, Kadia, Tapan M., additional, Borthakur, Gautam, additional, Jabbour, Elias J., additional, Pemmaraju, Naveen, additional, Yilmaz, Musa, additional, Short, Nicholas J., additional, Maiti, Abhishek, additional, Sasaki, Koji, additional, Masarova, Lucia, additional, Pierce, Sherry R., additional, Takahashi, Koichi, additional, Tang, Guilin, additional, Loghavi, Sanam, additional, Patel, Keyur P, additional, Andreeff, Michael, additional, Bhalla, Kapil N, additional, Garcia-Manero, Guillermo, additional, Ravandi, Farhad, additional, Kantarjian, Hagop M., additional, and Daver, Naval G., additional

Published
2022
Full Text
View/download PDF

10. Clinical outcomes associated with NPM1mutations in patients with relapsed or refractory AML

Author

Issa, Ghayas C., Bidikian, Aram, Venugopal, Sangeetha, Konopleva, Marina, DiNardo, Courtney D., Kadia, Tapan M., Borthakur, Gautam, Jabbour, Elias, Pemmaraju, Naveen, Yilmaz, Musa, Short, Nicholas J., Maiti, Abhishek, Sasaki, Koji, Masarova, Lucia, Pierce, Sherry, Takahashi, Koichi, Tang, Guilin, Loghavi, Sanam, Patel, Keyur, Andreeff, Michael, Bhalla, Kapil, Garcia-Manero, Guillermo, Ravandi, Farhad, Kantarjian, Hagop, and Daver, Naval

Abstract

•In relapsed or refractory AML, mutated NPM1has no impact on the risk of relapse or death.•The addition of venetoclax to salvage treatment for NPM1-mutated AML is associated with improved outcomes.

Published
2023
Full Text
View/download PDF

11. Clinical value of event-free survival in acute myeloid leukemia

Author

Maiti, Abhishek, primary, Kantarjian, Hagop M., primary, Popat, Vinita, primary, Borthakur, Gautam, primary, Garcia-Manero, Guillermo, primary, Konopleva, Marina Y., primary, DiNardo, Courtney D., primary, Verstovsek, Srdan, primary, Andreeff, Michael, primary, Kadia, Tapan M., primary, Ajufo, Helen O., primary, Goswamy, Rohit V., primary, Blanco, Carlos, primary, Velasquez, Miguel, primary, Daver, Naval G., primary, Pemmaraju, Naveen, primary, Pierce, Sherry R., primary, Wierda, William G., primary, Kornblau, Steven M., primary, Ravandi, Farhad, primary, and Cortes, Jorge E., primary

Published
2020
Full Text
View/download PDF

12. Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens

Author

Lachowiez, Curtis A., primary, Loghavi, Sanam, primary, Kadia, Tapan M., primary, Daver, Naval, primary, Borthakur, Gautam, primary, Pemmaraju, Naveen, primary, Naqvi, Kiran, primary, Alvarado, Yesid, primary, Yilmaz, Musa, primary, Short, Nicholas, primary, Ohanian, Maro, primary, Pierce, Sherry R., primary, Patel, Keyur P., primary, Qiao, Wei, primary, Ning, Jing, primary, Sasaki, Koji, primary, Takahashi, Koichi, primary, Jabbour, Elias, primary, Andreeff, Michael, primary, Ravandi, Farhad, primary, Kantarjian, Hagop M., primary, Konopleva, Marina, primary, and DiNardo, Courtney D., primary

Published
2020
Full Text
View/download PDF

14. Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis

Author

Boddu, Prajwal, primary, Kantarjian, Hagop M., additional, Garcia-Manero, Guillermo, additional, Ravandi, Farhad, additional, Verstovsek, Srdan, additional, Jabbour, Elias, additional, Borthakur, Gautam, additional, Konopleva, Marina, additional, Bhalla, Kapil N., additional, Daver, Naval, additional, DiNardo, Courtney D., additional, Benton, Christopher B., additional, Takahashi, Koichi, additional, Estrov, Zeev, additional, Pierce, Sherry R., additional, Andreeff, Michael, additional, Cortes, Jorge E., additional, and Kadia, Tapan M., additional

Published
2017
Full Text
View/download PDF

15. Co-occurrence of FLT3-TKD and NPM1mutations defines a highly favorable prognostic AML group

Author

Boddu, Prajwal, Kantarjian, Hagop, Borthakur, Gautam, Kadia, Tapan, Daver, Naval, Pierce, Sherry, Andreeff, Michael, Ravandi, Farhad, Cortes, Jorge, and Kornblau, Steven M.

Abstract

Although FLT3internal tandem duplication (ITD) mutations in acute myeloid leukemia (AML) confer an adverse prognosis, co-occurrence with a nucleophosphomin (NPM1) mutation partially improves response and survival outcomes. In contrast, simultaneous NPM1and FLT3tyrosine kinase domain (TKD) mutations were reported to improve response over that of an isolated NPM1mutation in one as yet unverified report. To validate this, we explored the impact of the co-occurrence of FLT3-TKD and NPM1mutations on clinical outcomes. Study populations included 21 patients (8%) with FLT3-TKD+NPM1+mutated, 18 patients (7%) with FLT3-TKD-only–mutated, 117 patients (44%) with NPM1-only–mutated, and 107 patients (41%) with FLT3-ITD+NPM1–mutated AML. Compared with NPM1+-only–mutated AML, FLT3-TKD/NPM1double mutation status was associated with a significantly superior relapse-free survival (median, not reached vs 18.3 months; P= .03) and a trend toward improved overall survival (OS). The presence of FLT3-TKD/NPM1double mutation status was an independent positive predictor in multivariable analysis. Allogeneic stem cell transplant did not improve outcomes in the FLT3-TKD/NPM1cohort. Consistent with historical data, the co-mutation status defined a highly favorable prognostic group characterized by high response rates and prolonged disease-free and OS. These study findings substantiate previous data describing this intriguing paradoxical cooperative effect. Our results emphasize the need for elucidating the mechanistic links between FLT3-TKD and NPM1in future molecular and murine model studies.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results